EKF Diagnostics, the in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyser.
In a scientific poster published by scientists at the Memorial Healthcare System, Hollywood, USA1, it was demonstrated that EKF’s GSP assay enhances the versatility of the Vista system for the specialised glycemic monitoring of diabetics with haemoglobinopathies, or conditions that affect red blood cell (RBC) lifespan.
Daily blood glucose and HbA1c are used as short and long term (3-4 month) measures of glycemic control respectively.
However, HbA1c values may be adversely affected by patients with haemoglobin variants or conditions that affect RBC lifespan such as anaemia and dialysis to name a few, while GSP as a 2-3 week indicator of blood glucose, is unaffected. Traditional NBT assays for fructosamine (or GSP), used as an alternative test for diabetes patients with haemoglobinopathies and pregnant women, suffer from a variety of interferences. Due to these analytical issues, the Memorial Healthcare System scientists required a reliable alternative that could be adapted to their existing analyser. Therefore, the EKF Diagnostics GSP assay was evaluated and validated using an open channel user defined method.
The scientific poster authors concluded that EKF’s GSP assay provides laboratories with a simple, sensitive and fast alternative glycemic monitoring test without the endogenous substance interference that are typically observed in NBT based colorimetric assays.
Reference: 1. Chittiprol S., Buzaki C., Tinckell H., Kiechle F.L. Validation of a new Glycated Serum Protein assay on the Siemens Vista analyzer. American Association for Clinical Chemistry (AACC) Annual Scientific Meeting - Scientific Poster Presentation (2016)
